MSLN and leukemia: Zhang et al. successfully obtained CAR (CD19)-iMacs and CAR (Mesothelin)-iMacs cells using the iPSC-derived CAR-iMacs approach and subsequently examined their antitumor potency by incubating with CD19-expressing K562 leukemia cells or Mesothelin-expressing OVCAR3/ASPC1 ovarian/pancreatic cancer cells, respectively, in vitro [70].